{
  "ptid_time": "137_S_0722_2010-11-19",
  "img_path": "/data/qiuhui/data/adni/images/137_S_0722/2010-11-19/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 61,558 mm³, 59.8% above the reference mean. With a Z-score of 1.43 (92.4th percentile), this represents mild enlargement; hippocampal volume measures 6,834 mm³, 9.6% below the reference mean. With a Z-score of -0.94 (17.5th percentile), this represents normal volume ; whole brain volume measures 1,149,800 mm³, 6.5% above the reference mean. With a Z-score of 0.85 (80.1th percentile), this represents normal volume ; entorhinal cortex volume measures 2,111 mm³, 48.5% below the reference mean. With a Z-score of -3.29 (0.1th percentile), this represents profound atrophy; fusiform gyrus volume measures 18,478 mm³, 1.9% below the reference mean. With a Z-score of -0.16 (43.5th percentile), this represents normal volume ; middle temporal gyrus volume measures 22,445 mm³, 5.2% above the reference mean. With a Z-score of 0.47 (67.9th percentile), this represents normal volume . ",
  "text_data": "Age is 74.1 years. Gender is Male. Education: 12 years. Handedness: Right. Race: White. MMSE: 29.0. MoCA: 28.0. Logical Memory: 12.0. APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 0.88 SUVR (moderate reduced). ",
  "true_diagnosis": "Diagnosis: CN.",
  "gpt_diagnosis": "**Reasoning:** The data shows profound atrophy in the entorhinal cortex (Z-score -3.29, 0.1th percentile), which is strongly associated with Alzheimer's pathology, while hippocampal volume is normal. Ventricular enlargement is mild, and other regions are within normal ranges. Despite normal cognitive scores (MMSE 29, MoCA 28), the entorhinal atrophy suggests early neurodegeneration.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)**  \n**Confidence:** **Medium** (Cognitive scores are intact, but entorhinal atrophy is a strong biomarker for early Alzheimer's-related decline.)  \n\n*Note: The absence of APOE4 and moderate AV45 (amyloid PET) reduction complicates the certainty, as classic Alzheimer’s would typically show stronger amyloid burden. Follow-up with CSF biomarkers or repeat imaging may clarify progression.*",
  "timestamp": "2025-07-26T16:16:37.520403"
}